On May 27, 2026 Genomic Testing Cooperative, a molecular diagnostics company advancing comprehensive cancer profiling through DNA and RNA analysis, reported it will exhibit and present research at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting. ASCO (Free ASCO Whitepaper) 2026 will bring together the global oncology community to explore high-impact cancer research, clinical advances, and new technologies shaping the future of cancer care. More than 3,400 abstracts are expected to be presented at this year’s meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

WHAT:
GTC will be available throughout ASCO (Free ASCO Whitepaper) 2026 to connect with media, oncology leaders, industry analysts, financial analysts, pharmaceutical companies, cancer centers, laboratories and potential strategic partners interested in the company’s comprehensive testing platform, cooperative business model and approach to precision cancer diagnostics.

WHEN:
May 29 to June 2, 2026

WHERE:
McCormick Place, Chicago – Booth #17146

GTC PRESENTATIONS AND AFFILIATED POSTERS:

Details for each presentation are available at genomictestingcooperative.com/asco2026/, and the posters will be posted here after ASCO (Free ASCO Whitepaper).

Session: Hematologic Malignancies | Lymphoma and Chronic Lymphocytic Leukemia

Defining APOBEC-like signature in diffuse large B-cell lymphoma and demonstration of distinct transcriptomic profile.

Date: Jun 1, 2026 – 9 AM – 12PM CDT

Abstract: 7075 Poster Board 573

Session: Breast Cancer | Metastatic

Dominant chromosomal abnormalities in breast cancer metastasis to CNS as compared with systemic metastasis demonstrated by liquid biopsy.

Date: Jun 1, 2026 – 1:30-4:30 PM CDT

Abstract: 1035 Poster Board 149

Session: Hematologic Malignancies | Leukemia, Myelodysplastic Syndromes, and Allotransplant

Distinction of FLT3-ITD transcriptomic signature from FLT3-TKD and the frequency of this signature in acute myeloid leukemia without FLT3 mutation.

Date: Jun 1, 2026 – 9 AM – 12PM CDT

Abstract: 6538 Poster board 331

Session: Developmental Therapeutics | Molecularly Targeted Agents and Tumor Biology

Comprehensive profiling and clinical utility of CSF-derived cell-free DNA/RNA for evaluation of solid and hematologic malignancies affecting the central nervous system.

Date: May 30, 2026

Abstract: 3066 Poster Board 203

Session: Hematologic Malignancies | Leukemia, Myelodysplastic Syndromes, and Allotransplant

TP53 mutation adoption of stromal-adhesion/neuronal-like programs as a driver of stress adaptation and acute myelogenous leukemia cell survival.

Date: Jun 1, 2026

Abstract: 6545 Poster Board: 338

Session: Hematologic Malignancies | Leukemia, Myelodysplastic Syndromes, and Allotransplant

A two-axis machine learning framework for cell-of-origin inference in AML: A proof-of-concept study.

Date: Jun 1, 2026

Abstract: 6540 Poster Board: 333

MEDIA AND ANALYST OPPORTUNITIES
Members of the media, industry analysts and financial analysts may schedule meetings with GTC leadership to discuss:

New research being presented at ASCO (Free ASCO Whitepaper) 2026

The role of comprehensive DNA and RNA testing in precision oncology
Liquid biopsy applications, including CSF-based testing for cancers affecting the central nervous system
GTC’s approach to hematologic malignancies, solid tumors and metastatic disease
The company’s cooperative model and opportunities for laboratories, oncology practices and strategic partners
GTC’s growth strategy, including opportunities to expand access to comprehensive molecular testing
WHY GTC MATTERS:
Cancer is complex, and treatment decisions increasingly depend on complete molecular information. GTC’s platform analyzes both DNA and RNA to help identify clinically meaningful biomarkers that more limited testing approaches may miss. GTC approach in RNA sequencing and utilization with artificial intelligence has lead to multiple new tests and discovery of unique biomarkers. For oncologists, pathologists, cancer centers, laboratories and research partners attending ASCO (Free ASCO Whitepaper), GTC offers a differentiated model designed to support comprehensive cancer profiling, clinical interpretation and broader access to precision diagnostics.

WHO:
GTC leaders available for interviews and briefings include:

Maher Albitar, MD, Founder, CEO and Chief Medical Officer
Ahmad Charifa, MD
Adam Zrinsky Albitar, MD
Jennifer Varca, President
Jeff Owen, VP, Marketing and International Sales
Colleen Zirpoli, VP, Sales
To schedule a meeting with GTC at ASCO (Free ASCO Whitepaper) 2026, contact Cara Stewart at [email protected] or +1 949-290-5563; details are available at genomictestingcooperative.com/asco2026.

(Press release, Genomic Testing Cooperative, MAY 27, 2026, View Source [SID1234666087])

On May 26, 2026 Biomunex Pharmaceuticals, a biopharmaceutical company specialized in the discovery and development of innovative immunotherapies based on bispecific and multi-specific antibodies, reported two new strategic collaborations with AI-driven companies, Gordion Bioscience and Tangramed Biotech. These partnerships are fully aligned with Biomunex’s ongoing strategy to further integrate relevant AI into all its scientific processes to further accelerate the discovery and development processes of novel immunotherapeutic approaches in oncology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the first research collaboration, Biomunex will work with Gordion Bioscience, a US-based AI-driven oncology company, specializing in patient-derived biological network analysis and computational target discovery, to identify novel bispecific target combinations in oncology. The objective is to reinforce Biomunex’s innovative pipeline with original pairs of targets and new differentiated therapeutic candidates for cancer treatment.

In a complementary approach, Biomunex has entered into a second research collaboration with Tangramed Biotech, a France-based AI-enabled biotech company, developing multimodal target-combination discovery approaches powered by biomedical data analytics. The objective is to uncover and prioritize actionable therapeutic opportunities, to identify novel target combinations that could leverage Biomunex’s proprietary BiXAb platforms. This collaboration is expected to leverage generative AI, for the identification of novel therapeutic candidates in solid tumors and hematological malignancies.

These two collaborations reflect Biomunex’s commitment to combining the scientific strength of its proprietary platform technologies with the capabilities offered by AI in several R&D axes, particularly to optimize target selection, shorten discovery timelines, and increase the probability of translational success.

"Biomunex has developed with BiXAb one of the most versatile and efficient technologies for the generation of bispecific antibodies. Gordion’s framework uncovers co-essential target pairs that conventional expression-based approaches often fail to detect. Gordion will systematically explore a broad landscape of target combinations, surfacing clinically differentiated pairs for breakthrough bispecific antibodies," adds Dr. Pawel Zawadzki, CEO of Gordion Bioscience.

"Translating the power of generative AI and biomedical data analytics into concrete and clinical impact is exemplified in this collaboration with Biomunex. By combining our AI-driven platform with Biomunex’s BiXAb technologies, we believe that Tangramed will help Biomunex further accelerate the identification of high-value target combinations to create next-generation immunotherapies in oncology," comments Dr. Jinchao Yu, CSO of Tangramed Biotech.

"Artificial intelligence has become a major driver of innovation in drug discovery. By combining our expertise in bispecific and multi-specific antibodies and our BiXAb platforms with the technologies developed by AI-driven companies, such as Tangramed Biotech and Gordion Bioscience, we are strengthening our ability to rapidly identify new therapeutic opportunities in oncology," comments Dr. Simon Plyte, CSO of Biomunex.

Dr. Pierre-Emmanuel Gerard, Founding President and CEO of Biomunex adds: "Biomunex has established for a long time a very cost- and time-effective process to bring disruptive innovation thanks to our BiXAb technologies, as well as our know-how in molecular modeling or in-silico design. These deals represent a step forward in our AI strategy, to accelerate even more our process to generate and develop new breakthrough clinical candidates".

One of the current Biomunex’s goals is indeed to further integrate AI in all parts of the company, not only for R&D programs, but also general corporate resources, such as finance, accounting, human resources & recruitment and legal topics.

(Press release, BIOMUNEX Pharmaceuticals, MAY 26, 2026, View Source [SID1234666085])

On May 26, 2026 BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, reported that the independent Data Safety Monitoring Board (DSMB) has issued its sixth consecutive positive recommendation following review of safety data from BriaCell’s pivotal Phase 3 Bria-ABC study of Bria-IMT plus immune checkpoint inhibitor (CPI) in patients with metastatic breast cancer (NCT06072612).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following its review, the DSMB raised no safety concerns and recommended that the study continue without modifications. DSMB meetings occur quarterly in accordance with the study protocol. BriaCell’s ongoing pivotal Phase 3 study is being conducted under Fast Track designation granted by the US Food and Drug Administration (FDA), reflecting the significant unmet medical need in metastatic breast cancer.

"We are highly encouraged by the sixth consecutive positive recommendation of the DSMB for continuation of BriaCell’s pivotal Phase 3 Bria-ABC study," said Dr. William V. Williams, President and Chief Executive Officer of BriaCell. "This important milestone represents another step forward in advancing BriaCell’s novel immunotherapy approaches for patients with urgent unmet medical needs."

(Press release, BriaCell Therapeutics, MAY 26, 2026, View Source [SID1234666084])

On May 26, 2026 Bionano Genomics, Inc. (Nasdaq: BNGO) reported publication of a peer-reviewed study in Modern Pathology showing that optical genome mapping (OGM) detected genomic abnormalities in 97.8% of T-cell acute lymphoblastic leukemia (T-ALL) cases — nearly double the 55% detection rate achieved by conventional cytogenetic analysis. Conducted by researchers at The University of Texas MD Anderson Cancer Center and Johns Hopkins University School of Medicine and representing one of the most comprehensive genomic analyses of T-ALL to date, the study underscores OGM’s potential to transform how this aggressive blood cancer is studied and understood.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

T-ALL is an aggressive form of pediatric and adult leukemia driven by a wide variety of complex genetic changes, many of which are too subtle or structurally complex to be detected by traditional methods. The disease is notoriously difficult to characterize fully, limiting the ability of researchers to study its biology, classify subtypes, and develop targeted therapies.

The 91-subject study compared OGM head-to-head against conventional karyotyping and next-generation sequencing (NGS) — the standard tools for evaluating T-ALL. Where karyotyping identified abnormalities in just 55% of cases, OGM found them in 97.8% of cases, and provided additional genomic insights beyond standard methods in approximately 70% of the cases — all from OGM’s single workflow.

Key Highlights:

91 cases: of T-ALL cases analyzed across three platforms — OGM, conventional karyotyping, and NGS — making this study the largest OGM study of T-ALL conducted to date.
High success rate for finding abnormalities: OGM identified chromosomal abnormalities in 97.8% of cases, compared to 55% by conventional karyotyping — a dramatic improvement in detection for a disease where missed findings can leave the biology incompletely understood.
Broader picture in 70% of cases: OGM delivered clinically relevant genomic information beyond karyotyping in approximately 70% of cases, uncovering abnormalities that standard methods missed — all without requiring additional testing.
24 known + 21 novel gene fusions identified: OGM detected gene rearrangements in 80% of cases, including 24 known recurrent fusions and 21 newly identified fusions, pointing to potential new targets for T-ALL research.
Comprehensive sequence variant and copy number profiling: OGM identified copy number changes in 93% of cases. NGS detected sequence variants in 92% of cases. The gene most frequently found to harbor variants was NOTCH1 (57% of cases).
Disease subtypes decoded: OGM uncovered distinct genomic patterns across T-ALL subtypes, supporting more precise biological classification of this heterogeneous disease.
OGM can streamline workflows for T-ALL. T-ALL presents particular challenges for standard genomic analysis: samples often yield poor-quality material for karyotyping, and many of the most biologically important genetic changes are subtle, small-scale, or driven by rearrangements in non-coding regions of the genome. Conventional approaches typically require multiple sequential analyses to piece together a complete picture — a process that is time-consuming, costly, and incomplete. OGM can address these limitations with a genome-wide approach that captures the full landscape of genetic variation in a single workflow.

"This publication further strengthens the growing body of evidence supporting OGM as a powerful tool for resolving the genomic complexity of challenging childhood and adult blood cancers like T-ALL, 50% of which remain unsolved by legacy methods, such as, karyotyping. This study, as one of the first and largest of its kind in T-ALL, demonstrates the complementarity that OGM and NGS can provide and shows how OGM can be particularly well-suited to T-ALL’s unique challenges — including poor sample quality, subtle rearrangements, and a wide range of genomic targets — capturing recurrent and novel alterations in a single pass that would otherwise require multiple sequential tests," said Alka Chaubey, PhD, FACMG, chief medical officer of Bionano. Dr. Chaubey continued, "the ability to uncover subtle and complex rearrangements in diseases like T-ALL can give researchers a far more complete picture of the biology — and reinforces why comprehensive structural variant analysis matters in blood cancer research."

(Press release, BioNano International Singapore Pte, MAY 26, 2026, View Source [SID1234666083])

On May 26, 2026 Calidi Biotherapeutics, Inc. (NYSE American: CLDI) ("Calidi" or "the Company"), a biotechnology company pioneering the development of targeted genetic medicines, reported that two abstracts showcasing the Company’s RedTail platform have been accepted for online publication at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting being held from May 29 to June 2, 2026 in Chicago, IL. The Company’s proprietary RedTail platform is a systemically delivered virotherapy platform engineered to selectively target tumors, remodel the tumor microenvironment, and enable high-level expression of therapeutic genetic payloads directly within tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company will present preclinical data on its lead program, CLD-401. CLD-401 is a systemically delivered virotherapy designed to selectively target tumors and enable high-level expression of IL-15 superagonist ("IL-15 SA"), a known T- and NK-cell activator, driving profound immune changes in the tumor microenvironment ("TME"), including the recruitment and activation of NK, NK-T, and gamma delta (γδ) T-cells that lead to a robust therapeutic response in immunocompetent animal models. The Company expects to file an IND for CLD-401 by the end of 2026.

The Company will also present preclinical data on CLD-501, the lead compound from its in situ T-cell engager ("TCE") approach. CLD-501 is a systemically delivered virotherapy designed to selectively target tumors and simultaneously enable the high-level in situ expression of a TROP-2 TCE and IL-15 SA.

"The data presented at ASCO (Free ASCO Whitepaper) demonstrate the potential for the RedTail platform as systemic virotherapy that can deliver genetic medicine to metastatic sites after systemic administration," said Antonio F. Santidrian, PhD, Chief Scientific Officer of Calidi. "The ability of CLD-401 to induce high levels of IL15-SA expression in the TME may drive activity in patients that have progressed on current IO therapies while the tandem expression of a TCE and a T-cell activator as seen with CLD-501 may overcome the barriers to TCE efficacy in solid tumors."

The Company continues to expand the functionality of the RedTail platform and is also actively pursuing strategic partnerships to accelerate clinical development and broaden the impact of its RedTail platform.

(Press release, Calidi Biotherapeutics, MAY 26, 2026, View Source [SID1234666082])